The effects of plasma chromium on lipid profile, glucose metabolism and cardiovascular risk in type 2 diabetes mellitus. A case - control study

PLoS One. 2018 Jul 5;13(7):e0197977. doi: 10.1371/journal.pone.0197977. eCollection 2018.

Abstract

Background: The study was aimed at determining the effect of plasma chromium concentration on the metabolism of glucose, and lipids and their subsequent cardiovascular risk in patients with type 2 diabetes in the Bolgatanga district of Ghana.

Material and methods: Fasting blood glucose and lipids profile were determined by enzymatic assay using the BT 5000® Random Access Chemistry Analyzer. Fasting serum insulin and High sensitive C-reactive protein were determined by ELISA, a solid phase direct sandwich immunoassay method. HOMA-IR, which is based on fasting blood sample for insulin and glucose concentrations measured in a single blood sample, was used to calculate insulin resistance. Plasma chromium was measured using an atomic Absorption Spectrometer.

Results: Patientswith diabeteshad significantly (p<0.0001) increased LDL, TC, TG, VLDL, insulin, CRP and HOMAIR and a significantly reduced plasma chromium (p<0.0001) (0.53± 0.02μg/l and 0.11±0.01μg/l control and case respectively). Low Cr (p ≤0.001) was associated with high blood pressure, obesity and lipid dysregulation. Plasma Cr significantly correlated negatively with blood pressure and LDL.

Conclusion: Lower plasma Cr level was associated with hyperglycaemia, hyperinsulinemia, hypertension, insulin resistance and high inflammation marker HsCRP.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Blood Glucose
  • C-Reactive Protein
  • Cardiovascular Diseases / blood*
  • Cardiovascular Diseases / complications
  • Cardiovascular Diseases / pathology
  • Chromium / blood*
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / pathology
  • Female
  • Humans
  • Insulin / blood
  • Insulin Resistance / physiology
  • Lipids / blood*
  • Lipoproteins, LDL / blood
  • Lipoproteins, VLDL / blood
  • Male
  • Middle Aged
  • Obesity / blood
  • Obesity / complications
  • Obesity / pathology
  • Risk Factors

Substances

  • Blood Glucose
  • Insulin
  • Lipids
  • Lipoproteins, LDL
  • Lipoproteins, VLDL
  • Chromium
  • C-Reactive Protein

Grant support

MAA received a Ghana Education Trust fund, but this fund was not applied directly to the research. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.